One recent night, three-plus months into our ongoing solitary confinement, we found ourselves laughing very hard at a classic Road Runner cartoon. We especially loved the moment when Wile E. Coyote stepped off a cliff then froze in mid-air as knowledge of his fate dawned on him. That image popped into our mind as we
Today’s guest post comes from Karl Neumann at Cozen & O’Connor. He was on the team that won this case, and sent us such a detailed description that we invited him to write it up himself – and he was kind enough to take us up on that offer. The title tells you what
Yesterday afternoon, only a few minutes after we saw the storm warning and cut short our walk with the Drug and Device Law Little Rescue Dogs, a brief but violent thunderstorm crashed through our neighborhood in the western suburbs of Philadelphia. (We note, parenthetically, that the adjective “violent” describes our weather with unprecedented and escalating
Bexis has been writing amicus curiae briefs for the Product Liability Advisory Council (“PLAC”) for a long time. He was introduced to PLAC by one of the best lawyers he (or anyone, for that matter) ever met, Edward W. “Neddie” Madeira, Jr., who recently passed away. Fare thee well, Neddie, you are missed.
Back
The Northern District of California did not mince words in its opinion in Rodman v. Otsuka America Pharmaceutical, Inc., 2020 WL 2525032 (N.D. Cal. May 18, 2020) and so neither will we. Plaintiff had three theories of failure to warn and a design defect claim and they all failed in grand fashion due in
The remanded pelvic mesh case, Sherer-Smith v. C.R. Bard, Inc., was recently wiped from the docket by summary judgment. See 2020 WL 1470962 (W.D. Wis. March 26, 2020). That’s news because, except for a couple of odd-ball cases (see Gray v. C. R. Bard, Inc., 2019 WL 6521972 (S.D.W. Va. Dec. 3,
Last year we posted about two major decisions by the New Jersey Supreme Court finally chopping the Accutane inflammatory bowel disease (“IBD”) litigation down to size. Our post here contains links to all of our posts over the years on the Accutane litigation. The point of note is that to get to those two decisions
The Ninth Circuit has not been great for us on Daubert. I suppose it is more accurate to say that the Ninth Circuit has not been great for those who oppose the introduction of unreliable scientific expert opinions. But that is usually us, the defendants resisting plaintiffs’ efforts to get to juries with scientific
The Holiday season is also the cinema season. We’re giddy about movies right now. Today sees the release of the trailer for No Time to Die, the 25th Bond film (counting only the “official” EON productions – sorry about that, Casino Royale (1967) and Never Say Never Again (1983)). No Time to Die (hereinafter
Today we offer another in our series of travel misadventures. Last weekend, we had the pleasure of visiting the Drug and Device Law Rock Climber (and seeing Lin-Manuel Miranda’s improvisational hip-hop show) in New York City. We took the train to Philadelphia then to the regional station closest to our home. Here we pause for